Health News

IRVINE, Calif.--(BUSINESS WIRE)--WM Technology, Inc. (“WM Technology” or the “Company”) (Nasdaq: MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced its decision to voluntarily delist its Class A common stock and warrants from The Nasdaq Global Select Market (“Nasdaq”). The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist its Class A common stock and warrants from Nasdaq and to deregister its...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of emp...

SAN FRANCISCO--(BUSINESS WIRE)--Latent, the clinical-AI company accelerating access to life-saving medications, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems. Modern medicine has advanced faster than the systems that deliver it. Today in the U.S., a patient and their doctor will sit together, look at a diagnos...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--GreenSTEM Technology Corp is proud to introduce BioProspector™ Fertilizer (BioPro), an exciting new product that uses biosafe fungi to improve plant tolerance to abiotic stress such as drought, extreme temperatures, salinity or nutrient deficiencies, such as in – but not exclusive to – mine sites. The product is ready for field testing, and GreenSTEM is looking for participants in field trials. Co-founder Susan Kaminskyj says, “One of our major motivati...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. “Clare brings more than three decades of industry experience,...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--InterVene, Inc., a privately held medical device company advancing interventional care for venous disease, today announced the successful completion of 30 cases using the Recana® Thrombectomy Catheter System. The cases were performed across the company’s limited US market release and its European first-in-human study. "We’ve had the privilege of partnering with some of the most experienced and knowledgeable physicians to reach this important milestone,” sa...

MIAMI--(BUSINESS WIRE)--Petwealth raises $1.7M, advancing at-home pet PCR diagnostics, AI health insights, and key partnerships in vet telehealth and pet service software....

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM   1. Details of the per...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026. Cash position as of March 31, 2026 GenSight Biologics’ cash and cash equivalents totaled €3.2 million...

MIAMI--(BUSINESS WIRE)--OpenEvidence debuts Dotflows: AI-native customization for clinicians to tailor workflows, automate tasks, and share community-driven medical prompts....